Cargando…

COVID-19: Hotspot hospital?- seroprevalence of SARS-CoV-2 antibodies in hospital employees in a secondary care hospital network in Germany: Intermediate results of a prospective surveillance study

PURPOSE: The objective of the ongoing study was to investigate how SARS-CoV-2 infection spread within two hospitals in North Rhine-Westphalia, Germany by testing the employees working in high-risk, intermediate-risk and low-risk-areas for the presence of SARS-CoV-2 IgG antibodies. Presented intermed...

Descripción completa

Detalles Bibliográficos
Autores principales: Hildebrandt, Anke, Hökelekli, Oktay, Uflacker, Lutz, Rudolf, Henrik, Gatermann, Sören G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier GmbH. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135189/
https://www.ncbi.nlm.nih.gov/pubmed/34049092
http://dx.doi.org/10.1016/j.ijheh.2021.113771
_version_ 1783695317156233216
author Hildebrandt, Anke
Hökelekli, Oktay
Uflacker, Lutz
Rudolf, Henrik
Gatermann, Sören G.
author_facet Hildebrandt, Anke
Hökelekli, Oktay
Uflacker, Lutz
Rudolf, Henrik
Gatermann, Sören G.
author_sort Hildebrandt, Anke
collection PubMed
description PURPOSE: The objective of the ongoing study was to investigate how SARS-CoV-2 infection spread within two hospitals in North Rhine-Westphalia, Germany by testing the employees working in high-risk, intermediate-risk and low-risk-areas for the presence of SARS-CoV-2 IgG antibodies. Presented intermediate results evaluate the first infection period until the end of September 2020. METHODS: The study “COVID-19: Hotspot hospital?- Seroprevalence of SARS-CoV-2 antibodies in hospital employees in a secondary care hospital network in Germany " is a prospective, single centre observational cohort study conducted at the St. Vincenz Hospital Datteln with 316 beds. The presented data include one other hospital: St. Laurentius Stift Waltrop, Germany with 172 beds. RESULTS: Between June 2020 and September 2020 we analyzed serum samples of 907 employees which represents 62.1% of all employees. Thirteen employees (1.4%), respectively 13/696 healthcare workers (HCWs) (1.9%) had detectable SARS-CoV-2 IgG antibodies. Among them, 4 (30.8%) were aware of COVID-19 exposure, and 5 (38.5%) reported clinical symptoms. HCWs working in high-risk areas had a seroprevalence rate of 1.6% (1/64), HCWs working in intermediate-risk area 1.7% (11/632) and 0.5% employees (1/211) in low-risk areas with no contact to patients were seropositive. CONCLUSION: Even if we treated COVID-19 positive patients, we found no clear evidence that infection was transmitted to HCWs in contact to these patients. As knowledge about SARS-CoV-2 transmission evolves, the concept of infection prevention must be continuously reviewed and adapted as needed to keep hospitals a safe place.
format Online
Article
Text
id pubmed-8135189
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier GmbH.
record_format MEDLINE/PubMed
spelling pubmed-81351892021-05-21 COVID-19: Hotspot hospital?- seroprevalence of SARS-CoV-2 antibodies in hospital employees in a secondary care hospital network in Germany: Intermediate results of a prospective surveillance study Hildebrandt, Anke Hökelekli, Oktay Uflacker, Lutz Rudolf, Henrik Gatermann, Sören G. Int J Hyg Environ Health Article PURPOSE: The objective of the ongoing study was to investigate how SARS-CoV-2 infection spread within two hospitals in North Rhine-Westphalia, Germany by testing the employees working in high-risk, intermediate-risk and low-risk-areas for the presence of SARS-CoV-2 IgG antibodies. Presented intermediate results evaluate the first infection period until the end of September 2020. METHODS: The study “COVID-19: Hotspot hospital?- Seroprevalence of SARS-CoV-2 antibodies in hospital employees in a secondary care hospital network in Germany " is a prospective, single centre observational cohort study conducted at the St. Vincenz Hospital Datteln with 316 beds. The presented data include one other hospital: St. Laurentius Stift Waltrop, Germany with 172 beds. RESULTS: Between June 2020 and September 2020 we analyzed serum samples of 907 employees which represents 62.1% of all employees. Thirteen employees (1.4%), respectively 13/696 healthcare workers (HCWs) (1.9%) had detectable SARS-CoV-2 IgG antibodies. Among them, 4 (30.8%) were aware of COVID-19 exposure, and 5 (38.5%) reported clinical symptoms. HCWs working in high-risk areas had a seroprevalence rate of 1.6% (1/64), HCWs working in intermediate-risk area 1.7% (11/632) and 0.5% employees (1/211) in low-risk areas with no contact to patients were seropositive. CONCLUSION: Even if we treated COVID-19 positive patients, we found no clear evidence that infection was transmitted to HCWs in contact to these patients. As knowledge about SARS-CoV-2 transmission evolves, the concept of infection prevention must be continuously reviewed and adapted as needed to keep hospitals a safe place. The Author(s). Published by Elsevier GmbH. 2021-06 2021-05-20 /pmc/articles/PMC8135189/ /pubmed/34049092 http://dx.doi.org/10.1016/j.ijheh.2021.113771 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Hildebrandt, Anke
Hökelekli, Oktay
Uflacker, Lutz
Rudolf, Henrik
Gatermann, Sören G.
COVID-19: Hotspot hospital?- seroprevalence of SARS-CoV-2 antibodies in hospital employees in a secondary care hospital network in Germany: Intermediate results of a prospective surveillance study
title COVID-19: Hotspot hospital?- seroprevalence of SARS-CoV-2 antibodies in hospital employees in a secondary care hospital network in Germany: Intermediate results of a prospective surveillance study
title_full COVID-19: Hotspot hospital?- seroprevalence of SARS-CoV-2 antibodies in hospital employees in a secondary care hospital network in Germany: Intermediate results of a prospective surveillance study
title_fullStr COVID-19: Hotspot hospital?- seroprevalence of SARS-CoV-2 antibodies in hospital employees in a secondary care hospital network in Germany: Intermediate results of a prospective surveillance study
title_full_unstemmed COVID-19: Hotspot hospital?- seroprevalence of SARS-CoV-2 antibodies in hospital employees in a secondary care hospital network in Germany: Intermediate results of a prospective surveillance study
title_short COVID-19: Hotspot hospital?- seroprevalence of SARS-CoV-2 antibodies in hospital employees in a secondary care hospital network in Germany: Intermediate results of a prospective surveillance study
title_sort covid-19: hotspot hospital?- seroprevalence of sars-cov-2 antibodies in hospital employees in a secondary care hospital network in germany: intermediate results of a prospective surveillance study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135189/
https://www.ncbi.nlm.nih.gov/pubmed/34049092
http://dx.doi.org/10.1016/j.ijheh.2021.113771
work_keys_str_mv AT hildebrandtanke covid19hotspothospitalseroprevalenceofsarscov2antibodiesinhospitalemployeesinasecondarycarehospitalnetworkingermanyintermediateresultsofaprospectivesurveillancestudy
AT hokeleklioktay covid19hotspothospitalseroprevalenceofsarscov2antibodiesinhospitalemployeesinasecondarycarehospitalnetworkingermanyintermediateresultsofaprospectivesurveillancestudy
AT uflackerlutz covid19hotspothospitalseroprevalenceofsarscov2antibodiesinhospitalemployeesinasecondarycarehospitalnetworkingermanyintermediateresultsofaprospectivesurveillancestudy
AT rudolfhenrik covid19hotspothospitalseroprevalenceofsarscov2antibodiesinhospitalemployeesinasecondarycarehospitalnetworkingermanyintermediateresultsofaprospectivesurveillancestudy
AT gatermannsoreng covid19hotspothospitalseroprevalenceofsarscov2antibodiesinhospitalemployeesinasecondarycarehospitalnetworkingermanyintermediateresultsofaprospectivesurveillancestudy